Jeffrey Leiden compensation by year
Vertex Pharmaceuticals Summary Compensation Table · all 8 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|
| Salary | $1,300,000 | $1,300,000 | $1,300,000 | $1,300,000 | $1,121,539 | $242,308 | $0 | $0 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Stock awards | $9,800,076 | $8,750,114 | $9,800,288 | $9,334,681 | $13,335,168 | $7,875,259 | $8,500,250 | $6,500,260 |
| Option awards | $4,060,397 | $3,700,877 | $4,243,973 | $4,572,039 | $0 | $0 | $0 | — |
| Non-equity incentive | $2,246,400 | $3,463,200 | $3,440,151 | $3,510,000 | $1,973,400 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| All other | $12,885 | $13,110 | $14,735 | $73,265 | $43,138 | $39,672 | $92,930 | $95,022 |
| Total | $17,419,758 | $17,227,301 | $18,799,147 | $18,789,985 | $16,473,245 | $8,157,239 | $8,593,180 | $6,595,282 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vertex Pharmaceuticals Inc DEF 14A filed April 4, 2024, accession 0001308179-24-000452, and prior-year filings.
How this page was built: the Vertex Pharmaceuticals Inc filed document, accession 0001308179-24-000452. Every figure is read from that document and cited to the page and table it appears in. Filed April 4, 2024.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 28,444 | $6,246,302 | — |
| RSU | 20,928 | $4,595,789 | — |
| PSU | 15,731 | $3,454,528 | — |
| PSU | 10,464 | $2,297,894 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Vertex Pharmaceuticals Inc's FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
35 Form 4 lines since the FY2023 proxy (filed April 4, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-02-24 | Tax withholding | — | 3,547 | $485.11 | 34,797 |
| 2026-02-18 | Tax withholding | — | 2,964 | $483.75 | 38,344 |
| 2026-02-17 | Grant or award | — | 8,269 | $0.00 | 41,308 |
| 2026-01-22 | Grant or award | — | 9,012 | $0.00 | 33,039 |
| 2025-12-04 | Exercise or conversion | 10b5-1 | 1 | $91.05 | 24,027 |
| 2025-12-04 | Exercise or conversion derivative | 10b5-1 | 1 | $0.00 | 0 |
| 2025-12-03 | Sale | 10b5-1 | 2,070 | $455.22 | 24,026 |
| 2025-12-03 | Sale | 10b5-1 | 7,899 | $445.56 | 67,298 |
The 8 most recent of 35 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Vertex Pharmaceuticals’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Reshma Kewalramani | Chief Executive Officer and President | $20,594,441 |
| Stuart Arbuckle | Executive Vice President and Chief Operating Officer | $8,998,949 |
| Charles Wagner | Executive Vice President and Chief Financial Officer | $7,371,751 |
| Jeffrey Leiden · this page | Executive Chairman | $6,595,282 |
| David Altshuler | Executive Vice President and Chief Scientific Officer | $6,541,100 |
Board service
Vertex Pharmaceuticals board · FY2021–FY2024How this board is paid
Company policy: Vertex Pharmaceuticals pays directors a $100,000 cash retainer and $400,000 in Options, RSUs, or 50/50 mix. As stated in Vertex Pharmaceuticals's FY2024 proxy.
The full Vertex Pharmaceuticals compensation record
free company briefThis page is one person within Vertex Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Vertex Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vertex Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.